Press Release
July 9, 2018

Abingworth Raises $315 Million for 12th Life Sciences Fund

The London Private Investment Funds team advised Abingworth on the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. ABV VII exceeded its target of $300 million and is Abingworth’s 12th fund, investing in life sciences companies in Europe and the US. The firm has funds under management of over $1.2 billion. The fund invests broadly across all stages of development including early and late-stage venture deals, Clinical Co-development, VIPEs (Venture Investments in Public Equities) and public equities.

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1.2 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.

The Goodwin team was led by partner Ajay Pathak, associate Ravi Chopra and partner Laura Charkin.

For additional details on the closing, please read Abingworth’s press release.